Interactive Training Session – Good Vigilance Practices (GVP)

Date: Wednesday, April 24, 2024
Time: 1:00 pm – 3:00 pm EDT
Fee: Members: $250; Non-Members: $395

Presented by Jackie Conant, Senior Consultant from Q&C Services an associate member of Cosmetics Alliance.

Intended for:
  • Pharmacovigilance
  • Regulatory Affairs
  • Quality Assurance
  • Compare and contrast the differences in requirements between natural health product (NHP) and drugs (DINs),
  • Learn how to recognize and differentiate what is a quality complaint and what is an adverse reaction,
  • Hear what Q&C is seeing in trends from a Compliance & Enforcement (C&E) perspective,
  • Help you prepare for a GVP inspection.

The session includes exercises, a quiz and a Q&A session.

Training Certificates are issued for your records to each individual successfully completing the quiz.

Individual logins are required for each participant to obtain a training certificate.

About the Trainer

Jackie Conant, M.Sc. 
Senior Consultant, Good Pharmacovigilance Practices

Q&C Services

Jackie Conant brings extensive expertise to the pharmaceutical industry, specializing in Drug Safety & Surveillance, Risk Management, and Risk Minimization Strategies. Notably, she played a crucial role in developing the ICH Guideline E2D on post-market safety surveillance, representing the generic pharmaceutical industry alongside government leaders and health regulators. With a focus on compliance, Jackie established a Global Pharmacovigilance Compliance function for a major generics manufacturer, implementing processes for quality management and risk management procedures, including signal detection and benefit-risk assessment throughout product lifecycles.

Her strategic support extends to corporate global Pharmacovigilance processes, ensuring internal and external compliance across affiliates and business partners worldwide. Serving on committees such as the IGPA ICH-E2D expert working group and corporate Medical Advisory Committee, Jackie provides valuable insight into health-hazard classification and data-mining techniques for risk assessment. She is adept at scientific literature review and preparation of aggregate safety reports, including Periodic Safety Update reports and Periodic Benefit-Risk reports.
Jackie’s leadership and dedication to excellence make her an invaluable resource in the field of Pharmacovigilance. Her passion for success and commitment to fostering an environment of innovation and motivation ensure that participants in her training sessions gain practical knowledge and valuable insights essential for navigating the complexities of the pharmaceutical industry.